Long-term survival case of a non-small cell lung cancer bone metastasis patient treated with bone cement, radiation and gefitinib

被引：2

作者：

Hou, W-T ^{[1
]}

Xie, X-Q ^{[2
]}

Luo, Y. ^{[1
]}

Yi, C. ^{[1
]}

Luo, F. ^{[1
]}

Kang, J-B ^{[3
]}

Wang, F. ^{[1
]}

Lu, Y. ^{[1
]}

Gong, Y-L ^{[1
]}

Wu, D-B ^{[4
]}

Qu, B-L ^{[5
]}

机构：

[1] Sichuan Univ, West China Hosp, West China Med Sch, Dept Med Oncol,Canc Ctr, Chengdu, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Crit Care Med, Chengdu, Sichuan, Peoples R China

[3] Peoples Liberat Army Gen Hosp, Dept Radiotherapy, Med Ctr 6, Beijing, Peoples R China

[4] Angang Grp Gen Hosp, Canc Hosp, Anshan, Liaoning, Peoples R China

[5] Peoples Liberat Army Gen Hosp, Dept Radiotherapy, Med Ctr 1, Beijing, Peoples R China

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2021年 / 25卷 / 06期

关键词：

Bone metastasis; Non-small cell lung cancer; Bone cement; Radiation; Gefitinib; CIRCULATING TUMOR-CELLS; RESISTANCE; MECHANISMS; THERAPY; BENEFIT; IMPACT;

D O I：

10.26355/eurrev_202103_25417

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: We explore the treatment of bone metastases in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We reported a 76-year-old female patient, who was diagnosed with NSCLC with bone metastasis eight years ago (stage IVA). Due to unbearable diarrhea, she refused chemotherapy, and we adopted local treatment, including local radiotherapy 50 Gy and bone cement to lumbar spinal metastases, 62 Gy local radiotherapy of primary lung tumor, TKI inhibitor gefitinib and zoledronic acid. RESULTS: She survived more than eight years and is still in follow-up. CONCLUSIONS: The median survival time for NSCLC patients with bone metastases is often less than 1 year. We reported the patient with more than eight years of survival, showed that some special cases can adopt the methods of local treatment including bone cement, treatment benefit patients, radiation therapy and targeted therapy in clinic to expand the survival.

引用

页码：2542 / 2547

页数：6

共 27 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[2] Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].

Coleman, RE .

CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176

[3]

Deschamps F, 2012, Diagn Interv Imaging, V93, P685, DOI 10.1016/j.diii.2012.06.009

[4] Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis [J].

Devriese, L. A. ;

Bosma, A. J. ;

van de Heuvel, M. M. ;

Heemsbergen, W. ;

Voest, E. E. ;

Schellens, J. H. M. .

LUNG CANCER, 2012, 75 (02) :242-247

[5] Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Fujita, Shiro ;

Kunimasa, Kei ;

Nanjo, Shigeki ;

Otsuka, Kyoko ;

Kaji, Reiko ;

Tomii, Keisuke ;

Iwasaku, Masahiro ;

Nishiyama, Akihiro ;

Hayashi, Hidetoshi ;

Morita, Satoshi ;

Ishida, Tadashi .

LUNG CANCER, 2011, 74 (02) :268-273

[6] Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer [J].

Kaira, Kyoichi ;

Naito, Tateaki ;

Takahashi, Toshiaki ;

Ayabe, Eriko ;

Shimoyama, Rai ;

Kaira, Rieko ;

Ono, Akira ;

Igawa, Satoshi ;

Shukuya, Takehito ;

Murakami, Haruyasu ;

Tsuya, Asuka ;

Nakamura, Yukiko ;

Endo, Masahiro ;

Yamamoto, Nobuyuki .

LUNG CANCER, 2010, 68 (01) :99-104

[7] Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer [J].

Kaneda, H ;

Tamura, K ;

Kurata, T ;

Uejima, H ;

Nakagawa, K ;

Fukuoka, M .

LUNG CANCER, 2004, 46 (02) :247-254

[8] Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer [J].

Krebs, Matthew G. ;

Sloane, Robert ;

Priest, Lynsey ;

Lancashire, Lee ;

Hou, Jian-Mei ;

Greystoke, Alastair ;

Ward, Tim H. ;

Ferraldeschi, Roberta ;

Hughes, Andrew ;

Clack, Glen ;

Ranson, Malcolm ;

Dive, Caroline ;

Blackhall, Fiona H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1556-1563

[9] The incidence and clinical impact of bone metastases in non-small cell lung cancer [J].

Kuchuk, Michael ;

Kuchuk, Iryna ;

Sabri, Elham ;

Hutton, Brian ;

Clemons, Mark ;

Wheatley-Price, Paul .

LUNG CANCER, 2015, 89 (02) :197-202

[10] Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates [J].

Langer, Corey ;

Hirsh, Vera .

LUNG CANCER, 2010, 67 (01) :4-11

← 1 2 3 →